Table S1 Baseline information of the subjects

| Patients No. | Gender | Age (years) | Clinical characteristics | Coffee consumption |
| :---: | :---: | :---: | :---: | :---: |
| 1 | F | 29 | Healthy and undergo MRI | 1-2 cups/day |
| 2 | M | 50 | Healthy and undergo MRI | 3-4 cups/day |
| 3 | M | 39 | Healthy and undergo MRI | 1-2 cups/day |
| 4 | F | 24 | Healthy and undergo MRI | 1-2 cups/day |
| 5 | M | 49 | Healthy and undergo MRI | 2-3 cups/day |
| 6 | F | 38 | Healthy and undergo MRI | 3-4 cups/day |
| 7 | M | 28 | Healthy and undergo MRI | 1-2 cups/day |
| 8 | M | 53 | Healthy and undergo MRI | 1-2 cups/day |
| 9 | M | 44 | Healthy and undergo MRI | 2-3 cups/day |
| 10 | F | 22 | Healthy and undergo MRI | <1 cup/day |
| 11 | F | 20 | Healthy and undergo MRI | <1 cup/day |
| 12 | F | 19 | Healthy and undergo MRI | <1 cup/day |
| 13 | M | 20 | Healthy and undergo MRI | <1 cup/day |
| 14 | M | 19 | Healthy and undergo MRI | <1 cup/day |
| 15 | F | 22 | Healthy and undergo MRI | <1 cup/day |
| 16 | F | 21 | Healthy and undergo MRI | <1 cup/day |
| 17 | M | 20 | Healthy and undergo MRI | <1 cup/day |
| 18 | M | 22 | Healthy and undergo MRI | <1 cup/day |
| 19 | F | 20 | Healthy and undergo MRI | <1 cup/day |
| 20 | M | 22 | Healthy and undergo MRI | <1 cup/day |
| 21 | F | 20 | Healthy and undergo MRI | <1 cup/day |
| 22 | F | 19 | Healthy and undergo MRI | <1 cup/day |
| 23 | F | 19 | Healthy and undergo MRI | <1 cup/day |
| 24 | M | 18 | Healthy and undergo MRI | <1 cup/day |
| 25 | M | 21 | Healthy and undergo MRI | No consumption |
| 26 | F | 23 | Healthy and undergo MRI | No consumption |
| 27 | F | 32 | Healthy and undergo MRI | No consumption |
| 28 | M | 20 | Healthy and undergo MRI | No consumption |
| 29 | M | 21 | Healthy and undergo MRI | No consumption |
| 30 | F | 25 | Healthy and undergo MRI | No consumption |
| 31 | F | 24 | Healthy and undergo MRI | No consumption |
| 32 | F | 18 | Healthy and undergo MRI | No consumption |
| 33 | F | 24 | Healthy and undergo MRI | No consumption |
| 34 | M | 20 | Healthy and undergo MRI | No consumption |
| 35 | F | 19 | Healthy and undergo MRI | No consumption |
| 36 | F | 21 | Healthy and undergo MRI | No consumption |
| 37 | M | 27 | Healthy and undergo MRI | No consumption |
| 38 | M | 24 | Healthy and undergo MRI | No consumption |
| 39 | F | 23 | Healthy and undergo MRI | No consumption |
| 40 | F | 23 | Healthy and undergo MRI | No consumption |
| 41 | M | 30 | Healthy and undergo MRI | No consumption |
| 42 | M | 33 | Healthy and undergo MRI | No consumption |
| 43 | M | 20 | Healthy and undergo MRI | No consumption |
| 44 | F | 24 | Healthy and undergo MRI | No consumption |
| 45 | F | 26 | Healthy and undergo MRI | No consumption |

[^0]Table S2 Cerebral metabolites in the thalamus voxel measured by MRS in healthy adult subjects pre-coffee, and 30 and 120 min post-coffee

| Metabolite | Coffee consumption | Pre-coffee, mean $\pm$ SD | Post-coffee 30 min , mean $\pm$ SD | $\begin{aligned} & \text { Post-coffee } \\ & 120 \text { min, } \\ & \text { mean } \pm \text { SD } \end{aligned}$ | Interaction effect | Main effects |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  | Time $\times$ group ( P value) | Time (P value) | Group (P value) |
| GABA ${ }^{+}$ | - | $3.75 \pm 0.42$ | $3.48 \pm 0.34$ | $4.09 \pm 1.27$ | - | 0.011* | - |
| Glu | $\geq 1$ cup/day | $8.07 \pm 0.66$ | $8.61 \pm 0.76$ | $8.00 \pm 1.59$ | 0.007* | 0.088 | <0.0001* |
|  | <1 cup/day | $8.87 \pm 0.85$ | $9.24 \pm 0.98$ | $8.94 \pm 0.54$ |  |  |  |
|  | NCD | $9.50 \pm 1.20$ | $9.12 \pm 0.80$ | $9.74 \pm 0.56$ |  |  |  |
| GPC/GPC + PCH | $\geq 1$ cup/day | $2.38 \pm 0.19$ | $2.35 \pm 0.14$ | $2.43 \pm 0.08$ | 0.001* | 0.012* | 0.001* |
|  | <1 cup/day | $1.96 \pm 0.05$ | $2.13 \pm 0.13$ | $2.01 \pm 0.17$ |  |  |  |
|  | NCD | $2.04 \pm 0.17$ | $2.11 \pm 0.183$ | $1.98 \pm 0.26$ |  |  |  |
| Ins | $\geq 1$ cup/day | $4.34 \pm 0.31$ | $4.25 \pm 0.33$ | $4.31 \pm 0.25$ | 0.001* | 0.009* | 0.298 |
|  | <1 cup/day | $3.99 \pm 0.49$ | $4.54 \pm 0.59$ | $4.34 \pm 0.65$ |  |  |  |
|  | NCD | $4.16 \pm 0.37$ | $4.38 \pm 0.58$ | $4.03 \pm 0.35$ |  |  |  |
| $\mathrm{Cr}+\mathrm{PCr}$ | $\geq 1$ cup/day | $7.59 \pm 0.33$ | $7.71 \pm 0.18$ | $7.96 \pm 0.10$ | 0.001* | 0.060 | 0.003* |
|  | <1 cup/day | $8.20 \pm 0.49$ | $8.28 \pm 0.30$ | $8.21 \pm 0.24$ |  |  |  |
|  | NCD | $7.88 \pm 0.45$ | $7.80 \pm 0.23$ | $7.67 \pm 0.17$ |  |  |  |
| Glx | $\geq 1$ cup/day | $11.33 \pm 0.45$ | $11.21 \pm 1.56$ | $11.13 \pm 2.09$ | 0.001* | 0.002* | 0.014* |
|  | <1 cup/day | $11.82 \pm 1.36$ | $12.79 \pm 1.37$ | $11.92 \pm 1.24$ |  |  |  |
|  | NCD | $12.68 \pm 1.72$ | $12.17 \pm 1.65$ | $12.63 \pm 0.54$ |  |  |  |

Two-way repeated-measures ANOVA was performed. *, statistically significant results ( $\mathrm{P}<0.05$ ). MRS, magnetic resonance spectroscopy; SD, standard deviation; GABA ${ }^{+}, \gamma$-aminobutyric acid-positive macromolecule; Glu, glutamate; NCD, non-coffee drinkers; GPC, glycerylphosphocholine; PCH, phosphocholine; Ins, myo-inositol; Cr, creatine; PCr, phosphocreatine; Glx, glutamate and glutamine; ANOVA, analysis of variance.

Table S3 Cerebral metabolites in the posterior cingulate cortex voxel measured by MRS in healthy adult subjects pre-coffee, and 30 and 120 min post-coffee

| Metabolite | Coffee consumption | Pre-coffee, mean $\pm$ SD | Post-coffee 30 min , mean $\pm$ SD | $\begin{aligned} & \text { Post-coffee } \\ & 120 \text { min, } \\ & \text { mean } \pm \text { SD } \end{aligned}$ | $\frac{\text { Interaction effect }}{\text { Time } \times \text { group ( } \mathrm{P} \text { value) }}$ | Main effects |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  | Time (P value) | Group (P value) |
| $\mathrm{GABA}^{+}$ | $\geq 1$ cup/day | $3.09 \pm 0.28$ | $3.18 \pm 0.27$ | $3.02 \pm 0.36$ | 0.064 | 0.213 | 0.089 |
|  | <1 cup/day | $3.21 \pm 0.24$ | $3.06 \pm 0.61$ | $3.25 \pm 0.26$ |  |  |  |
|  | NCD | $3.02 \pm 0.52$ | $3.12 \pm 0.21$ | $3.38 \pm 0.32$ | <0.0001* | <0.0001* | 0.028* |
| Glu | $\geq 1$ cup/day | $10.26 \pm 0.18$ | $9.93 \pm 1.08$ | $10.39 \pm 1.44$ |  |  |  |
|  | <1 cup/day | $10.72 \pm 0.31$ | $10.11 \pm 0.59$ | $10.62 \pm 0.72$ |  |  |  |
|  | NCD | $10.60 \pm 0.71$ | $10.14 \pm 0.85$ | $10.34 \pm 0.61$ | 0.016* | <0.0001* | 0.026* |
| GPC/GPC + PCH | $\geq 1$ cup/day | $1.32 \pm 0.13$ | $1.43 \pm 0.24$ | $1.42 \pm 0.24$ |  |  |  |
|  | <1 cup/day | $1.10 \pm 0.12$ | $1.09 \pm 0.09$ | $1.09 \pm 0.07$ |  |  |  |
|  | NCD | $1.19 \pm 0.12$ | $1.19 \pm 0.12$ | $1.20 \pm 0.10$ | 0.528 | 0.107 | 0.009* |
| Ins | $\geq 1$ cup/day | $4.95 \pm 0.04$ | $4.88 \pm 0.21$ | $5.05 \pm 0.40$ |  |  |  |
|  | <1 cup/day | $5.16 \pm 0.23$ | $4.97 \pm 0.50$ | $5.14 \pm 0.53$ |  |  |  |
|  | NCD | $5.53 \pm 0.50$ | $5.08 \pm 0.43$ | $5.34 \pm 0.46$ |  |  |  |
| $\mathrm{Cr}+\mathrm{PCr}$ | $\geq 1$ cup/day | $7.66 \pm 0.35$ | $7.41 \pm 0.22$ | $7.78 \pm 0.37$ | 0.354 | 0.131 | 0.035* |
|  | <1 cup/day | $7.31 \pm 0.36$ | $7.38 \pm 0.35$ | $7.40 \pm 0.36$ |  |  |  |
|  | NCD | $7.23 \pm 0.32$ | $7.14 \pm 0.48$ | $7.16 \pm 0.31$ |  |  |  |
| Glx | $\geq 1$ cup/day | $14.07 \pm 0.37$ | $13.59 \pm 0.83$ | $14.65 \pm 1.96$ | <0.0001* | $<0.0001^{*}$ | 0.239 |
|  | <1 cup/day | $14.39 \pm 0.39$ | $14.17 \pm 1.00$ | $15.02 \pm 1.77$ |  |  |  |
|  | NCD | $14.07 \pm 1.01$ | $13.61 \pm 1.53$ | $14.52 \pm 1.07$ |  |  |  |

Two-way repeated-measures ANOVA was performed. *, statistically significant results ( $\mathrm{P}<0.05$ ). MRS, magnetic resonance spectroscopy; SD, standard deviation; GABA ${ }^{+}, \gamma$-aminobutyric acid-positive macromolecule; Glu, glutamate; NCD, non-coffee drinkers; GPC, glycerylphosphocholine; PCH, phosphocholine; Ins, myo-inositol; Cr, creatine; PCr, phosphocreatine; Glx, glutamate and glutamine; ANOVA, analysis of variance.


[^0]:    No., number; M, male; F, female; MRI, magnetic resonance imaging

